Another replacement to warfarin?? someday

Links to news stories of interest to heart patients.

Moderator: Moderators

Post Reply
User avatar
Posts: 8664
Joined: April 18th, 2009, 7:19 pm
Location: Broomfield, Colorado

Another replacement to warfarin?? someday

Post by freckles1880 » June 23rd, 2011, 5:05 am

I just love the way they say “non-inferior” and “If ultimately approved” Bob ... 2011_06_22

ARISTOTLE: Apixaban noninferior to warfarin in AF patients
June 22, 2011 | Shelley Wood Princeton, NJ and New York, NY –

Topline results from the ARISTOTLE trial, comparing apixaban (Eliquis, Pfizer/Bristol-Myers Squibb [BMS]) to warfarin in subjects with atrial fibrillation [AF] and risk factors for stroke, suggest that the oral direct factor Xa inhibitor is noninferior to the older standard for the prevention of stroke and systemic embolism [1].

According to preliminary results of the study, released late Wednesday, apixaban also "met the key secondary endpoints of superiority on efficacy and on ISTH (International Society on Thrombosis and Haemostasis) major bleeding compared to warfarin."
Full results of the trial will be presented August 28 at the European Society of Cardiology 2011 meeting in Paris, France.

ARISTOTLE enrolled over 18 000 AF patients in over 1000 centers in roughly 40 countries, the press release notes. The trial randomized patients to either a twice-daily dose of apixaban 2.5 mg, or dose-adjusted warfarin.

If ultimately approved, apixaban would compete in this indication against dabigatran (Pradaxa, Boehringer Ingelheim), which is already on the US and other markets, as well as rivaroxaban (Xarelto, Bayer/Johnson & Johnson), still waiting for US approval. Rivaroxaban demonstrated noninferiority to warfarin in the ROCKET AF trial.

Earlier this year, apixaban proved itself superior to aspirin in the 5599-patient AVERROES study, conducted in patients with AF, at risk for stroke, who were not suitable candidates for warfarin therapy as reported by heartwire. Preliminary AVERROES results were also released early, after a predefined interim analysis by the independent data monitoring committee saw a clear and "clinically important reduction in stroke and systemic embolism."

The first approval for apixaban was last month, in Europe, where regulators granted it approval for use in the 27 countries of the EU for the prevention of venous-thromboembolic (VTE) events in adult patients who have undergone elective hip- or knee-replacement surgery.
Last edited by freckles1880 on June 27th, 2011, 2:03 pm, edited 1 time in total.
Reason: Learning how

Medtronic-Visia AF implanted 7-8-2016 stayed with the with 6947 Sprint Quattro Secure lead. Original ICD implant 2-4-2009. ICD turned off 10-6-17 as stage 4 lung cancer taking over.
Major heart attack, carcinogenic shock and quad bypass 10-13-08 post myocardial infarction, old inferior MI complicated by shock and CHF, combined, Atherosclerosis, abdominal aortic Aneurysm, Seroma 7 cm, left leg. Stent in the left main vein 10-7-2014

My "Wardens" are my bride of 54+ years and my daughters.

Post Reply